Axulus
Veteran Member
When a generic drug formulation goes from $13.50 per pill to $750 each, the company making it is essentially putting a “Kick Me” sign on their back.
But unless you’ve been offline or away from the news for the last month, you’ll know that’s exactly what happened when Turing Pharmaceuticals’ CEO Martin Shkreli announced a price increase for Daraprim, a patented formulation of the antiprotozoal drug, pyrimethamine.
The off-patent drug is used to treat toxoplasmosis, a disease caused by a protozoan that can infect pregnant women and the fetus, as well as immunocompromised patients such as those with HIV/AIDS or cancer.
Turing purchased the rights to the Daraprim formulation of pyrimethamine from Impax Pharmaceuticals in August for $55 million.
As Shkreli made the rounds of cable news, financial channels, and social media, he drew the ire of patients, politicians, and even pharmaceutical societies for the price increase. He has since said that the price will be revisited and lowered. But as of this morning, a one-month supply of Daraprim (30 tablets of 25 mg pyrimethamine) retails between $22,000 and $24,000 across large pharmacies chains such as CVS, Kroger KR -2.70%, Target TGT -5.17%, Walmart, Walgreens, and Rite-Aid, among others. Mr. Shkreli has not responded to a request for a telephone interview.
In response, and as an extension of their ongoing compounding pharmacy services, Imiprimis Pharmaceuticals announced yesterday that it would be offering patient-specific, custom formulations of pyrimethamine together with leucovorin, a folic acid relative often given separately to offset some of pyrimethamine’s side effects.
The price? As low as 100 capsules for $99.
http://www.forbes.com/sites/davidkr...native-to-turings-daraprim-for-toxoplasmosis/